Article Text

Download PDFPDF
Renal Protection of Losartan 50 mg in Normotensive Chinese Patients With Nondiabetic Chronic Kidney Disease
  1. Pei-Cheng Shen, MD,
  2. Li-Qun He, MD, PhD,
  3. Xue-Jun Yang, MD, PhD,
  4. He-Xin Cao, MD, PhD
  1. From the Department of Nephrology, ShuGuang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Traditional Chinese Internal Medicine e-institute of Shanghai University; Shanghai Key, Laboratory of Traditional Chinese Clinical Medicine (grant number C10dz2220200), Shanghai, PR China.
  1. Received January 7, 2012, and in revised form June 17, 2012.
  2. Accepted for publication June 23, 2012.
  3. Reprints: Li-Qun He, MD, PhD, Department of Nephrology, ShuGuang Hospital, Pudong, 528 ZhangHeng Rd, Shanghai 201203, PR China. E-mail: spc720216{at}
  4. Supported by Ministry of Scientific technology of China Grant (201007005), National Natural Science Foundation of China Grant (81173219), Shanghai Science & Technology Commission Grant (11DZ1973100 and 12ZR1432400), E-Institute of TCM Internal Medicine of Shanghai Municipal Education Commission Grant (E03008), the Chinese Medicine project of Shanghai Municipal Health Bureau (2008L046A), and Innovative Research Team in Universities, Shanghai Municipal Education Commission Grant.


Aims Nondiabetic chronic kidney disease (CKD) is the leading major cause of end-stage renal disease in developing countries including China. Among the 5 stages of CKD, it is critical to retard the progression of stage 3 because renal disorder could accelerate aggravation behind that stage. Data suggest that high dosages of angiotensin receptor blockers (ARBs) could retard the progression of renal disease in hypertensive and/or diabetic patients. Nevertheless, in daily practice of nephrology, quite a number of nondiabetic patients with CKD who are normotensive do not tolerate even moderate dosages of ARBs because of adverse effects such as systemic hypotension, epically for Chinese patients. The aim of this study was to investigate the renoprotective effects of relatively low dosages of ARBs in normotensive Chinese patients with nondiabetic stage 3 CKD.

Methods A prospective, randomized, parallel-group, open-label study was performed over a period of 12 months. A total of 238 enrolled patients were randomly allocated to treatment with losartan 50 mg (n = 119) or placebo (n = 119). All patients were followed up at 2-month intervals. At each visit, blood pressure was measured, and urinalysis and serum biochemistry tests were performed.

Results Finally, 112 patients given losartan and 114 patients given placebo completed the study. In the losartan group, there was a significant and biphasic time-dependent decline in proteinuria during therapy (1.72 ± 0.47 to 0.99 ± 0.48 g/d; P < 0.001). Conversely, placebo did not simultaneously change the amount of proteinuria (1.73 ± 0.49 to 1.64 ± 0.50 g/d; P = 0.337). Estimated glomerular filtration rate remained stable during the entire study period in the patients given losartan (44.8 ± 8.1 to 44.1 ± 7.7 mL/min per 1.73 m2; P = 0.120) but were significantly reduced in the placebo group (44.5 ± 8.5 to 39.1 ± 7.4 mL/min per 1.73 m2, P < 0.001). The changes in blood pressure were kept constant in the 2 groups. All adverse events were minimal and nonfatal.

Conclusions For normotensive patients with nondiabetic stage 3 CKD, therapy with a daily dose of losartan, 50 mg, may perform effective renoprotection without changing blood pressure and be generally safe and well tolerated.

Key Words
  • nondiabetic renal disease
  • normotensive
  • losartan
  • proteinuria
  • renal protection

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.